developed-europe-header

Developed Europe

Sterile Focus Brands are the leading contributor to the region. The region holds key manufacturing sites which form the base of our strategic growth plans. The API site at Oss, supported by its satellite operation at Sioux City, supplies APIs worldwide. The Notre Dame de Bondeville and Bad Oldesloe sites are strategically important manufacturers for the Group.

Key Countries

France,
Germany,
Italy,
The Netherlands,
United Kingdom

Contribution to Group revenue

pic-1europe

Revenue contribution - by therapeutic category

pic-2europe
  • The Developed Europe pharmaceutical sector was valued at USD207 billion as at 31 December 2018
  • EU5* represent 77% of the value in Europe^ injectable Anaesthetics market with a 2 year CAGR of 7% p.a. in value

* EU5: France, Germany, Italy, Spain and the United Kingdom
^ IQVIA definition. Europe EU28 member states (including EU5) plus Switzerland.

Source: December 2018 IQVIA

STATISTICS

Number of products launched:

Nil

(2018: nil)

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:

0 – 2 years

USD38 million

3 – 5 years

Nil

Number of product recalls:

4

(2018: 7)

Average staff turnover:

9,2%

(2018: 8,4%)

Number of work-related fatalities:

Nil

(2018: nil)

Number of permanent employees:

june-01


Revenue
2019
R’million
2018 (CER)
R’million
change
%
Total12 32913 022 (7)
Regional Brands1 7791 894(6)
Sterile Focus Brands5 6025 935(6)
Thrombosis Brands2 1912 267(3)
Total Commercial Pharmaceuticals3 4113 668(7)
Total Manufacturing revenue7 3817 829(6)
Finished dose form4 7145 193(9)
Active pharmaceutical ingredients627666(6)
Total4 0874 527(10)

Note: Commercial Pharmaceuticals revenue is disclosed by customer geography and manufacturing revenue by place of manufacture.